Drug Profile
HCP 1405
Alternative Names: HCP1405Latest Information Update: 07 Sep 2016
Price :
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoporosis
Most Recent Events
- 19 Aug 2016 Phase-III clinical trials in Osteoporosis (unspecified route)